According to studies [6,7,8], humanized anti-HER2 antibodies like trastuzumab and pertuzumab, as well as selective estrogen receptor modulators (SERMs) like tamoxifen and toremifene, represent the gold standard for treating patients with breast cancers that are ER and HER2 positive, respectively. Here, ERBB2 is linked to breast carcinoma.